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Abstract Bioactives can be defined as: ‘‘Constituents in
foods or dietary supplements, other than those needed to meet
basic human nutritional needs, which are responsible for
changes in health status’’ (Office of Disease Prevention and
Health Promotion, Office of Public Health and Science,
Department of Health and Human Services in Fed Reg
69:55821–55822, 2004). Although traditional nutrients, such
as vitamins, minerals, protein, essential fatty acids and
essential amino acids, have dietary reference intake (DRI)
values, there is no such evaluative process for bioactives. For
certain classes of bioactives, substantial scientific evidence
exists to validate a relationship between their intake and
enhanced health conditions or reduced risk of disease. In
addition, the study of bioactives and their relationship to dis-
ease risk is a growing area of research supported by
government, academic institutions, and food and supplement
manufacturers. Importantly, consumers are purchasing foods
containing bioactives, yet there is no evaluative process in
place to let the public know how strong the science is behind
the benefits or the quantitative amounts needed to achieve
these beneficial health effects. This conference, Bioactives:
Qualitative Nutrient Reference Values for Life-stage Groups?,
explored why it is important to have a DRI-like process for
bioactives and challenges for establishing such a process.
Keywords Bioactives  Dietary reference intakes 
Non-essential nutrients  Adequate intake
Why it is important to have a DRI-like process
for the evaluation of bioactives
Bioactives are important to human health, they are an
active area of research, and consumers are purposefully
purchasing foods containing them. Substantial evidence
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exists that specific bioactives beneficially affect health.
This conference heard from three experts on bioactives: Dr.
Cesar G. Fraga on flavanols; Dr. Joseph Levy on lycopene
and other tomato carotenoids; and Dr. Mark Messina on
soybean isoflavones. A few of their major points are dis-
cussed here, since the overall goal of the conference was to
discuss the feasibility of applying a dietary reference intake
(DRI)-like process to the evaluation of bioactives rather
than a scientific discussion on bioactives themselves, the
reader is referred to a number of key papers for more
information in support of a specific bioactive and decreased
risk of a disease or other health-related condition. There is
strong evidence for the effect of flavanols on decreased risk
of cardiovascular disease and associated risk factors. This
evidence includes demographic data and human interven-
tions, and it is mechanistically supported by animal and
ex vivo studies [10]. (-)-Epicatechin is the compound better
studied [24]; however, other flavanols and flavonoids could
share these protective actions [30]. Another important class
of bioactives is isoflavones derived from soybean.
Although it is not possible to infer a direct causal rela-
tionship, case–control and prospective epidemiologic
studies show isoflavone intake via soyfoods is associated
with a lower risk of several chronic diseases including
breast [32] and prostate [33] cancer, and among women,
coronary heart disease (CHD) [18] and osteoporosis [17,
34]. Furthermore, there is relatively solid evidence that
isoflavones increase flow-mediated dilation in post-meno-
pausal women with impaired endothelial function [6] and
there is suggestive, but limited evidence, that isoflavones
reduce carotid intima media thickness [12]. The most
impressive clinical data exist for the alleviation of meno-
pausal hot flashes [27]. Lycopene and other tomato
carotenoids have been found to decrease blood pressure in
pre-hypertensive patients as well as reduce post-prandial
blood-oxidized low-density lipoproteins [5, 7, 16, 22].
Research on bioactives is a significant portion of diet,
nutrition and disease portfolios of governments, at univer-
sities, and at food manufacturers. Consumers are interested
in optimal health and are purposefully purchasing foods
containing bioactives. However, there is no evaluative
process in place to inform the public about the strength of
the science behind the purported benefits of a specific bio-
active of interest, nor is there information on how much of a
particular bioactive is necessary to be of benefit. If there
were a process to evaluate the strength of the science behind
the intake of a bioactive and decreased risk of disease (or
other health condition), standards would be set for this
research, studies could be compared across laboratories, and
consumers and health professionals could have more con-
fidence in what they were eating; and the field could move
forward more quickly. If that science base were combined
with a recommended intake value, assessments could be
made as to whether or not populations or specific age groups
were meeting that recommendation and consumers would
know the overall contribution of a food product to the
recommended amount.
Having a DRI value increases the status of a bioactive and
makes it part of nutrition public policy. Without a DRI value, it
is unlikely that bioactive information will be incorporated into
national nutrition intake surveys such as NHANES (National
Health and Nutrition Examination Survey) in the US. National
nutrition surveys describe the amount of nutrients being
consumed by representative populations, and then those
intake values are compared to a DRI to determine whether the
population is eating too much or too little of that substance. If
too little, the substance might be called an ‘‘at risk’’ nutrient,
and education campaigns to improve people’s intakes (within
one’s calorie allotment) could be implemented. Thus, not
having reference intake values limits the ability to develop
messaging to the public regarding bioactives for which there is
solid scientific evidence of their health-enhancing effects.
Importantly, health professionals (such as physicians, physi-
cian assistants, nurses, and dietitians) who may offer advice to
clients on what they should be eating, would be more com-
fortable recommending bioactives if they have gone through a
rigorous evaluation process. In most countries, the overall
nutrition policy is called ‘‘dietary guidance’’. Although this
guidance is food rather than nutrient based, the food recom-
mendations are derived from the DRI values for the nutrients.
For example, the philosophy of the US Dietary Guidelines is
that if one follows the recommendations of the guidelines, one
will automatically meet the DRI values for all nutrients [20].
Thus, dietary guidance is another important way that infor-
mation on bioactives with substantial science behind their
efficacy could be transmitted to consumers. For a summary of
the advantages of having a DRI-like process for the evaluation
of bioactives, see Table 1.
Dietary fiber is an example of a bioactive with a DRI
value. Although dietary fiber is a non-essential nutrient, it
does have an officially recommended intake value [14].
This means that the amount of fiber in a food product is on
most fact-based food labels throughout the world. It is also
generally included in the questionnaires on national food
intake surveys so that information is available as to whe-
ther or not the DRI value for fiber is being met. It also
means that it is considered and promoted in dietary guid-
ance. Dietary fiber is thus of concern to consumers who are
looking to increase it in their diets.
What are the challenges to establishing such a system
and how can those challenges be met
The process for determining nutrient reference values in the
US and Canada changed significantly in 1994 when several
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kinds of reference values were introduced and articulated in
the 1994 publication, How Should The Recommended
Dietary Allowances Be Revised [9]. There were two major
changes: (1) that values could be based on reduced risk of a
disease and (2) that there were additional values other than
the recommended dietary allowance (RDA), i.e., estimated
average requirement, adequate intake (AI), and upper level
(UL). A conclusion of this report was that the ‘‘reduction in
risk of chronic disease is a concept that should be included
in the formulation of future RDAs where sufficient data for
efficacy and safety exist [9] ’’. This conclusion represented
a ‘‘new paradigm’’ from what had previously existed. Using
these criteria, four DRI values have since been set based on
chronic disease: osteoporosis and fractures for calcium and
vitamin D, dental caries for fluoride, CHD for fiber, and a
combination of endpoints including salt sensitivity, kidney
stones, and blood pressure for potassium [28]. Thus, this
suggests that bioactives could qualify for a DRI value if
they could show strong science behind reduced risk of
disease.
Demonstrating reduced risk of disease with a bioactive
is more difficult than it is to show prevention of a deficiency
outcome with an essential nutrient. A major difference
between bioactives and essential nutrients (i.e., vitamins,
minerals, essential fatty acids, and essential amino acids) is
that the absence of bioactives in the diet does not result in a
deficiency disease, whereas the absence of an essential
nutrient eventually results in deficiency symptoms (e.g.,
lack of vitamin C and scurvy, thiamin and beriberi, iron
and anemia). This difference means that a DRI value would
have to be based on an endpoint other than a deficiency
disease. As shown above, this could be decreased risk of a
chronic disease, but showing cause and effect with a bio-
active and chronic disease is more difficult than when the
disease is specific nutrient related. In other words, if vita-
min C intake is inadequate, 100 % of the deficient people
will eventually get scurvy. This is not the case for chronic
disease which is affected by multiple nutrients, and is also
impacted by other non-nutrient factors (e.g., gender, age,
and genetics) [28].
Dr. Ben van Ommen challenged the concept of relating
health to just decreased risk of disease and suggested that
in quantifying the health effects of bioactives ‘‘we might
need to consider in greater depth what health is, what
mechanisms are involved in maintaining health, and how to
best quantify these’’. A pioneer in this new area of ‘‘opti-
mal health,’’ he considers health to be appropriate adap-
tation to a continuously changing environment—and food
Table 1 Why it is important to have a DRI-like process for the evaluation of bioactives
Importance Example Benefit for having a DRI-like value
Bioactives are important to human health For example, there is strong science behind the
relationship between flavanols and decreased
risk of cardiovascular disease [10, 15];
isoflavones and lower risk of several chronic
diseases [18, 27, 32]; and lycopene and other
tomato carotenoids and decreased blood
pressure [5, 7, 16, 22]
A major benefit would be that they would be
recognized as being important to health and
evaluated accordingly. Investigators,
regulatory agencies, consumers would all know
how strong the science was behind science
messaging on these compounds
Bioactives are a significant portion of diet
and disease research portfolios
Governments, Universities, and Food
Manufacturers are supporting studies on
bioactives
Standards would be set so that studies could be
compared across laboratories
Consumers are interested in optimal
health and are purposefully purchasing
foods containing bioactives
This was part of the rationale for setting DRI
values for bioactives in China
Consumers would benefit from strengthened
knowledge that they were making decisions
based on science and they would also have a
target to aim for in terms of intake
Having a DRI value increases the status
of a bioactive and makes it part of
nutrition public policy
Substances that have DRI values are regularly
evaluated in populations to see if that
population is meeting established DRI values
If the bioactive is part of the intake assessment of
nutrients/foods, then we will learn whether or
not that population is actually meeting the DRI
value, or if it is an ‘‘at risk’’ nutrient
The process by which a bioactive is
evaluated would set standards which
would raise the level of science
Such requirements as having a formal definition,
and an approved method of analysis would
help comparing studies across laboratories
Using common methods of analysis and a
common definition would allow studies to
build on each other and advance the science
more rapidly
With a transparent process for evaluation,
the results would provide science-based
recommendations for improving diets
Health professionals such as doctors, dietitians,
and educators would be more comfortable
making diet recommendations
Messaging on intake of bioactives would be
science based
Having an intake value would set a goal
for incorporating bioactives into diets
Consumers would know whether a food was a
good source of that bioactive, or how much one
would need to eat in order to reach the intake
value
Having a target intake value would discourage
messaging on products that suggest they are a
good source of a specific bioactive when they
only contain a negligible amount
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is a key part of that changing environment. He calls this
adaptive capacity ‘‘phenotypic flexibility’’ and states that it
is key to maintenance of overall homeostasis ‘‘and thus to a
healthy life’’. He and his research group have also devel-
oped ways to test for ‘‘phenotypic flexibility’’ by stressing
specific components of the system that maintain homeo-
stasis and evaluating the stress response reactions. These
response reactions usually appear to be more informative
and sensitive than their homeostatic counterpart. A classic
example is the oral glucose tolerance test versus fasting
glucose, and numerous other comparable ‘‘challenge bio-
markers’’ that are now being developed [23, 29]. If
accepting decreased risk of disease as an endpoint for a
DRI value was a paradigm shift, Dr. van Ommen’s
emphasis on ‘‘phenotypic flexibility’’ is definitely a new
paradigm shift which should become more widely accepted
as an evaluation of efficacy for a bioactive as the research
to measure this flexibility is validated.
Issues regarding the setting of life-stage DRI values
for bioactives
Dr. Stephanie Atkinson discussed possible approaches for
determining life-stage DRI values for bioactives using
information from previous DRI recommendations devel-
oped for infants, children, and youth as an example [1]. She
suggested using three age groupings to establish DRI val-
ues for bioactives: (1) infants to 1 year of age; (2) children
1–8 years; and (3) individuals over 8 years. For Infants to
1 year of age, she suggested using human milk as a ‘‘ref-
erence’’. For children 1–8 years, in the absence of clinical
trials, it was suggested that AI values be derived from
population-based intake data associated with health out-
comes. For those over age eight, the suggestion was to
derive the value from existing data on biomarkers of
chronic disease or extrapolation from adults. The rationale
and the cautions for each of these recommendations were
provided. Issues in establishing life-stage DRIs for bioac-
tives vary greatly from one substance to another. For
example, in infants, intakes from human milk bioactive
substances such as nucleotides [25], carnitine [2], lutein
[3], and glycoconjugate sugars [19, 26] have been used to
derive safe levels of addition of such compounds to infant
formulas. Evidence of the biological benefit of addition of
these substances to the health of formula-fed infants is
inconsistent, but no adverse effects have been identified. A
lack of response to addition of a bioactive to formula may
relate to the variable bioavailability of a bioactive
depending on whether it is found in breast milk or added to
formula. For example, approximately four times more
lutein is needed in infant formula than is naturally present
in human milk to achieve similar infant serum lutein
concentrations [3]. For the case of dietary fiber, using
human milk as a reference for infants 7–12 months of age
cannot be done because of the absence of this substance in
milk. Remaining challenges include selection of the best
model (approach): For example, objectively differentiating
between the various age groups on a basis other than age
itself seems logical, if difficult. Also, the development of
recommended intakes or maximal effect ranges is another
choice.
Establishing safety of bioactives and adjusting
for different population groups may not be the same
as it is for essential nutrients
Dr. David Richardson discussed the process of establishing
the safety of bioactives. For nutrients and other dietary
ingredients, the limitations on safety are commonly set
through identifying a ‘‘Tolerable Safe UL’’. This is done by
identifying any ‘‘hazard’’ associated with high intakes,
establishing a dose–response relationship, evaluating the
uncertainty and selecting a composite ‘‘safety factor,’’ and
then calculating an UL value. This procedure cannot be
applied when no hazard can be identified (as with many
bioactives). However, there is an alternative risk assess-
ment approach that is based on the highest observed intake
(HOI) method developed by FAO/WHO [8] and included
in Codex Guidelines [6]. The HOI is defined as the highest
level of intake observed with the available data of
acceptable quality, showing an absence of adverse effects.
Since most bioactives have no known hazard, the HOI is an
important alternative approach to setting quantitative value
limits on the amounts of bioactives that may be considered
safe.
Even if there is agreement on this general approach, the
problem remains that most safety data are derived from
studies on adult subjects designed to look for benefit rather
than harm. Scaling the healthy adult values to give confi-
dent estimates of the amounts to be deemed safe in sub-
population groups is difficult. Nonetheless, an adult UL or
HOI value is needed to give an appropriate basis for pol-
icies directed to other population groups. Most DRI values
fall well below the ULs/safe ULs, but some high intakes
can approach or exceed the safe UL. A narrow range
between a DRI and upper safe level may be unjustified
when there is a lack of evidence of a demonstrable adverse
effect/toxicity at current levels above an upper safe level. If
intakes exceed the UL/HOI, the significant uncertainties
about the safe level are more likely to indicate that the
intake is not the problem but rather the application of a safe
level based on inadequate data. In practical terms, adverse
effects are more often observed with inadequate intakes
rather than excessive intakes. Clearly, care and scientific
judgment must be taken in the use of a safe UL as the
benchmark in the selection of ULs/HOIs for bioactives.
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A sustainable approach is needed for the evaluation
of efficacy and intake recommendations for bioactives
Lessons learned from South Korea
There is growing interest in establishing a DRI-like system
for setting intake values for bioactives [4, 11]. Although
South Korea does not have a DRI system for establishing
intake values for bioactives, they do have an evaluative
process together with a process to determine intake values.
Dr. Namsoo Chang explained this process for South Korea.
The Health Functional Food (HFF) Act was enacted in
2004 with the goal of ensuring the safety of HFF with
certain health claims for consumer information. At its
inception the HFF covered products in the form of tablets,
capsules, powders, granules, pastes, gels, jellies, and bars
that were intended to enhance and preserve human health
and contained one or more functional ingredients or con-
stituents. In 2008, the scope was extended to include
conventional foods and other diet supplements.
What is unique about the HFF act in South Korea is that
unlike other countries, the government of South Korea is
endorsing a particular product with a HFF ‘‘seal’’. There
are two types of HFF, generic and product-specific. The
generic type (shown in Table 2) contains both 28 essential
nutrients and 55 non-nutrients. Both the nutrients and non-
nutrients are considered to have substantial efficacy and
safety data to have been considered for the generic cate-
gory. All of these substances listed on the generic health/
Functional Food Code include health claims and intake
recommendations. This generic type HFF is most analo-
gous to establishing a process for evaluation of efficacy and
intake values for DRIs, although they are not called DRIs
by the South Korean Government.
If the bioactive is not on the generic type list of func-
tional ingredients, then it needs to follow a process and
receive approval. Manufacturers submit a dossier for
comprehensive scientific evaluation of safety and efficacy,
which is reviewed by the Government and Advisory
Committees. The application must consist of any data on
the history of safe use, manufacturing processes, recom-
mend intake levels, toxicological data, clinical data,
nutritional evaluation data, and bioavailability data.
Soy isoflavones (discussed in this conference) have a
generic health claim which is that they help to maintain
bone health. The isoflavone content of common soybean
products in Korea is known, as is the isoflavone intake in
South Korea. Although no safety data were available in
Korea, the safe intake level for isoflavones was adopted
from the Japanese standards. A recommended intake is set
at 24–27 mg/day as aglycone soybean isoflavones. Nota-
bly, a caution is stated for infants, children, pregnant and
lactating women, and individuals who have an allergy to
soybean, and individuals who are sensitive to estrogen. A
generic claim for lutein (a bioactive found in tomatoes)
also exists. The health claim is, ‘‘helps eye health by
maintaining the density of macular pigments which can be
decreased by aging’’. Based on review of existing litera-
ture, the intake recommendation was set at 10–20 mg
lutein/day with a warning for yellowing of skin if taken at
excessive amounts. In addition, a recommendation for
intake of all-trans lycopene at 5.7–15 mg/day is provided
based on the health claim for tomato extracts as an anti-
oxidant. This recommendation is accompanied by a caution
for pregnant and lactating women and for children.
Flavonoids and lycopene are listed in the product-specific
Table 2 Functional ingredients listed in the South Korean Health/
Functional Food Code (Generic Type)
Nutrients Non-nutrients
Vitamin A Alkoxyglycerol Banaba leaf extract
Vitamin D Aloe gel Evening primrose seed
extract





Beta carotene Chlorella Ginko leaf extract
Vitamin B1 CLA Green tea extracts
Vitamin B2 Coenzyme Q10 Guava leaf extract
Vitamin B6 Fructooligosaccharide Haematococcus extract
Vitamin B12 Gamma-linoleic acid Japanese apricot extract
Niacin Ginseng Milk thistle extract
Vitamin C Glucosamine Propolis extract
Pantothenic
acid
L-theanine Saw palmetto extract
Folic acid Lecithin Functional fiber
Biotin Lutein Guar gum/hydrolyzates
Calcium MSM Glucomannan
Magnesium Mucopolysaccharide Indigestible maltodextrin
Potassium N-acetylglucosamine Oat fiber
Zinc Octacosanol Soy fiber
Copper Omega-3 fatty acids Tree ear
Selenium Phosphatidylserine Wheat fiber




Iodine Probiotics Corn bran
Molybdenum Red ginseng Inulin
Chrome Red yeast rice Psyllium husk
Dietary fiber Soy isoflavone Polydextrose
Essential fatty
acids





category, rather than the generic category. A flavonoid
database is available for commonly consumed food by
Koreans based on the USDA and Japanese flavonoid dat-
abases, which were developed in 2009. Flavonoids have
been linked to reduced risk for chronic diseases and
improved health outcomes, and six subclasses of flavonoids
are identified by structure.
Currently, the Ministry of Health and Welfare is revis-
ing the South Korean DRIs and plans to release the revised
version in 2015. Although it was recently decided that
bioactive substances will not be included in the 2015 ver-
sion of the DRIs, the need to establish DRIs for bioactive
substances was raised. If there were to be a DRI value for
bioactives, it would most likely be the AI value. The AI is
defined as ‘‘The recommended average daily intake level
based on observed or experimentally determined approxi-
mations or estimates of nutrient intake by a group (or
groups) of apparently healthy people that are assumed to be
adequate—used when an RDA cannot be determined’’
[13]. Importantly, South Korea may be able to contribute to
establishing ULs for bioactives, since they have a post-
market surveillance system on health/functional foods.
They are operating an online system for adverse events
data collection from consumers, manufacturers, and
healthcare professionals. They have the integrated database
on products and safety data and are in the process of doing
statistical modeling to determine a cause effect relationship
of any adverse event.
Setting specific proposed levels for bioactive compounds:
Recent experiences in China
Professor Yang Yuexin described the process for setting a
special category of DRIs (called specific proposed level;
SPL) in China. This new category is used to evaluate and
assign an intake value for bioactives. This is the only
country, of which we are aware, that has actually estab-
lished DRI values for bioactives. The China Nutrition
Society, similar to the Institute of Medicine in the US,
changed their intake evaluation process for nutrients from
only RDAs to DRIs. This change was initiated in 2000 and
resulted in 32 DRI values for nutrients. In 2010, they ini-
tiated the incorporation of a SPL for non-nutrients and a
proposed Intake that is based on reducing the risk of non-
communicable chronic disease and improving optimal
health. Their stated rationale as to why they consider the
SPL a DRI value is that both traditional medicine and
modern nutrition research have deepened the understand-
ing of plant compounds; and also because consumers are
widely consuming these bioactive substances in China. In
2010, they had seven different expert review panels con-
taining a total of 87 experts develope the DRIs for China to
be released in 2014. One of the seven panels was on ‘‘non-
nutrients,’’ and 21 experts were involved in this panel. The
goal of this panel was to develop DRI values for water,
fiber, and 18 phytochemicals (SPLs). The SPLs reflect the
current state of scientific knowledge and are published as a
series of reports by the Chinese Nutrition Society. Both
SPLs and ULs are set for bioactives. Table 3 shows the
‘‘non-nutrients’’ that were evaluated by the Chinese DRI
process.
The Chinese Nutrition Society has acknowledged that
there are some bioactives that ‘‘like some other nutrients,
are essential for reaching the full (genetically-determined)
lifespan’’. They have termed these nutrients as ‘‘life span
essential’’ [31]. The Chinese experience in establishing
DRI-like values for bioactives should be followed closely,
and they should be acknowledged as being the pioneers in
this area.
Setting a high bar for entrance into the evaluation
system
One issue with setting up a DRI-like process for the
evaluation of bioactives is the very wide range of the
strength of the science behind the intake of a bioactive and
a purported reduced risk of disease. For some bioactives,
little research has been conducted, whereas for others there
are 20–30 years of research in support of a protective
effect. A concern is that the evaluators would have to be
dealing with requests when there was insufficient infor-
mation to apply the process. One suggestion to offset this
challenge is to set a high standard for ‘‘entrance into the
evaluative process’’. Dr. Joanne Lupton discussed potential
entrance criteria as necessary information before a bioac-
tive could be considered for a DRI-like evaluation process
(see Table 4). Setting these nine criteria as essential for
consideration for evaluation serves several goals: It mini-
mizes the effort of the evaluator; and importantly, it sets a
standard, if met, that investigators and funding sources















could design their research to meet, knowing that there
would be a certain level of credibility if they were to do so.
Summary, conclusion, and next steps
The speakers were in consensus that providing a frame-
work for the evaluation of bioactives could be of benefit to
scientists working in this field, to funders of the research, to
governments, and importantly to consumers. However,
they were also aware of the potential challenges to estab-
lishing such a framework. Clearly, there is a difference
between determining intake values for essential nutrients
and bioactives, and thus the basis of the intake value cannot
be on a single-nutrient deficiency disease. Nonetheless,
other endpoints such as reduced risk of disease may be
applicable. Basing a DRI value on reduced risk of disease
has been used for four nutrients that have DRI values.
Alternatively, the AI value was considered by some to be
an appropriate value for consideration as by definition it
can reflect the current intake of specific healthy popula-
tions. Setting life-stage values for bioactives is also a
challenge, but Dr. Atkinson suggested a different model for
consideration. Instead of concentrating on the bioactive,
per se, she suggested establishing goals for life stages. For
example, for early life, it might be ‘‘optimal development’’
and markers for that could be body composition, or
Table 4 Proposed criteria for a bioactive to qualify for evaluation
Criterion Additional information Rationale for criterion
A definition of the substance
which is commonly accepted
Definition should match the method of analysis Makes it easier to build a database of efficacy of
bioactive if substances with the same definition are
compared
A method of analyzing the
substance which is consistent
with the definition
Preferably backed up by a multi-center analysis such
as an AOAC method
Facilitates comparing studies across laboratories.
Need a definition and an approved method of
measuring so that intake values can be determined,
and if populations are meeting recommended intake
values
Database of the amount of the
bioactive in foods
Preferably global and updated on a regular basis as
new foods come on the market
To determine the amount of this bioactive currently
in the food supply and enable determining how
much people are consuming. Also necessary for
baseline data for clinical trials and input into
epidemiological studies
Prospective cohort studies Both sexes, showing decreased risk of a disease such
as CVD with increased intake of the bioactive.
Must be able to isolate the specific bioactive versus
other bioactives. Best if the bioactive is also
measured in blood/urine, etc. in subset of
population and supports food intake data.
Relationship to the disease should be consistent
with clinical trials
Dose–response data or at least highest quintile versus
lowest quintile for the bioactive will help to set
level of efficacy
Clinical trials on digestion,
absorption, activation,
transport, excretion of the
substance
Important to understand the level of absorption and
what substances interfere with that absorption, also
what the active molecule is and how long it stays in
the blood
This information is useful for determining intake and
factors that affect intake, transport, activation, etc
Clinical trials on efficacy and
dose–response data
Conducted in healthy populations. Bioactive must be
measured. Accepted endpoint linked to decreased
risk of the particular disease. If surrogate marker,
must be ‘‘accepted’’ by regulatory agencies
Need dose–response data to determine the efficacious
level, and determine intake values
Safety data at the level of intake
that might be anticipated
Ideally would include safety data for special
populations such as children, pregnant or lactating
women
Need this information even if the bioactive is
considered generally regarded as safe (GRAS).
GRAS means ‘‘safe for intended use’’
Systematic Reviews and/or meta
analyses showing efficacy
In the US, the Institute of Medicine now requires
systematic reviews for setting DRI values (most
recent was calcium and vitamin D). The US Dietary
Guidelines now requires these also
Having a systematic review that shows efficacy is a
real plus and may be necessary, e.g., a Cochrane
review. These reinforce the need to have major




This is not required but is a very large plus if it is
available
Scientists/evaluators of the research are more
comfortable if there is an explanation, particularly




cognitive/behavioral outcomes. For child/adolescent, the
DRI value could be based on early biomarkers that are
sensitive indicators of chronic disease risk. Then, bioac-
tives that were shown to affect those outcomes could
receive intake values for that life stage. This model war-
rants development and consideration. Another challenge is
establishing an UL value for bioactives in the absence of
any evidence of toxicological effects. Here, it appears that
there is an extensive literature on risk/benefit systems
which should be considered for application to bioactives.
Finally, the logistics of how to set the framework, who is
the ‘‘keeper’’ of the system, and what it would take for a
bioactive to be considered in this framework requires
serious consideration. A proposed next step would be a
workshop with representation from all key stakeholders to
discuss the challenges to having a framework for the
evaluation of bioactives and how those challenges may be
overcome.
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